enGene Holdings Inc. (Nasdaq: ENGN), a clinical-stage genetic medicines company with its lead non-viral program EG-70 undergoing pivotal trials for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), announced the election of Paul Hastings and Wouter Joustra to its Board of Directors…
UCB, a global biopharmaceutical company, announced that the Journal of Neurology has published data from the Phase 3 RAISE study and the ongoing RAISE-XT open-label extension (OLE) study on the long-term effects of zilucoplan on fatigue in adult patients with…
Astellas Pharma Inc. will present new research from its innovative cancer therapies portfolio at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31 to June 4. Sixteen abstracts will be showcased, including pivotal trial data supporting…
Sanofi, the largest private contributor to France’s health ecosystem security and independence, announced a €1 billion investment to expand bioproduction at its sites in Vitry-sur-Seine, Le Trait, and Lyon Gerland. This initiative will create over 500 jobs, enhancing France’s capacity…
AbbVie (NYSE: ABBV) and Gilgamesh Pharmaceuticals have announced a collaboration and option-to-license agreement aimed at developing next-generation therapies for psychiatric disorders. This partnership combines AbbVie’s psychiatric expertise with Gilgamesh’s innovative research platform to discover novel neuroplastogens. Classic psychedelic compounds offer…
Be Biopharma, Inc. (“Be Bio”), a trailblazing company in the development of Engineered B Cell Medicines (BCMs), unveiled new preclinical findings today, showcasing the production of active ALP by a BCM. This breakthrough underscores BCMs’ potential as a treatment avenue…
Shionogi & Co., Ltd. (based in Osaka, Japan; CEO: Isao Teshirogi, Ph.D.) and Maze Therapeutics, Inc. (headquartered in South San Francisco, California, USA; CEO: Jason Coloma, Ph.D.) have finalized an exclusive worldwide licensing agreement for MZE001. This novel therapeutic candidate…
Shionogi, in collaboration with Nagasaki University (Administrative Office: Nagasaki; President: Takeshi Nagayasu, M.D., Ph.D.), the National Institute of Infectious Diseases (Head Office: Shinjuku-ku, Tokyo; Director: Takashi Wakita), and the non-profit research and development organization Medicines for Malaria Venture (MMV), has…
CRISPR Therapeutics (Nasdaq: CRSP), a company dedicated to pioneering gene-based medicines for severe illnesses, has unveiled its financial performance for the first quarter ending March 31, 2024. CEO and Chairman of CRISPR Therapeutics, Dr. Samarth Kulkarni, highlighted the notable progress…
AstraZeneca has confirmed the successful conclusion of its equity investment agreement with Cellectis, a clinical-stage biotech firm. The investment, along with a research collaboration deal unveiled in November 2023, aims to harness Cellectis’ proprietary gene editing technologies and manufacturing capabilities…
Astellas Pharma Inc. (TSE: 4503) and Poseida Therapeutics, Inc. (NASDAQ: PSTX) have announced a strategic collaboration between Astellas’ subsidiary Xyphos Biosciences, Inc. and Poseida. The agreement aims to develop innovative convertibleCAR® programs, merging the unique cell therapy platforms of both…
Summary of Financial Highlights: In the first quarter of 2024, the company experienced significant growth across various metrics: Overall, the company demonstrated robust growth in revenues and product sales, despite challenges such as increased operating expenses and a shift in…